Agenus Inc
AGEN3.840USD
+0.150+4.07%
收盤 11/06, 16:00（美東）報價延遲15分鐘
115.22M總市值
虧損本益比TTM
關於 Agenus Inc 公司
Agenus Inc. 是一家免疫腫瘤學 (IO) 公司，專注於癌症和傳染病，擁有一系列免疫藥物。該公司專門開發激活人體免疫系統對抗癌症和感染的療法。其產品線包括免疫調節抗體、過繼細胞療法（通過 MiNK Therapeutics, Inc.）和疫苗佐劑（通過 SaponiQx, Inc.）。其主要關注點是免疫腫瘤學，其多樣化的產品線由其內部能力支持，包括現行良好生產規範 (cGMP) 製造和臨牀運營平臺。其最先進的抗體候選藥物是 botensilimab（一種多功能免疫細胞激活劑和人類 Fc 增強細胞毒性 T 淋巴細胞抗原 4 (CTLA-4) 阻斷抗體 (AGEN1811)）和 balstilimab（一種程序性死亡受體-1 (PD-1) 阻斷抗體）。其產品線包括幾類免疫療法：檢查點抑制劑、免疫激活劑和腫瘤微環境調節劑。
Agenus Inc簡介
公司代碼AGEN
公司名稱Agenus Inc
上市日期Feb 04, 2000
CEODr. Garo H. Armen, Ph.D.
員工數量316
證券類型Ordinary Share
年結日Feb 04
公司地址3 Forbes Rd
城市LEXINGTON
上市交易所NASDAQ Capital Market Consolidated
國家United States of America
郵編02421-7305
電話17816744400
網址https://agenusbio.com/
公司代碼AGEN
上市日期Feb 04, 2000
CEODr. Garo H. Armen, Ph.D.
Agenus Inc公司高管
名稱
名稱/職務
職務
持股
持股變動
Ms. Christine M. Klaskin
Ms. Christine M. Klaskin
Vice President - Finance
Vice President - Finance
23.48K
+205.07%
Mr. Thomas L. (Tom) Harrison
Mr. Thomas L. (Tom) Harrison
Independent Director
Independent Director
22.08K
+35.46%
Mr. Brian J. Corvese
Mr. Brian J. Corvese
Independent Director
Independent Director
4.60K
--
Wright (Timothy R)
Wright (Timothy R)
Lead Independent Director
Lead Independent Director
2.77K
--
Dr. Garo H. Armen, Ph.D.
Dr. Garo H. Armen, Ph.D.
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
--
--
Mr. Richard Goldberg
Mr. Richard Goldberg
Chief Development Officer
Chief Development Officer
--
--
Dr. Steven O'Day, M.D.
Dr. Steven O'Day, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Jennifer S. Buell, Ph.D.
Dr. Jennifer S. Buell, Ph.D.
Director
Director
--
--
Ms. Susan F. Hirsch
Ms. Susan F. Hirsch
Independent Director
Independent Director
--
--
名稱
名稱/職務
職務
持股
持股變動
Ms. Christine M. Klaskin
Ms. Christine M. Klaskin
Vice President - Finance
Vice President - Finance
23.48K
+205.07%
Mr. Thomas L. (Tom) Harrison
Mr. Thomas L. (Tom) Harrison
Independent Director
Independent Director
22.08K
+35.46%
Mr. Brian J. Corvese
Mr. Brian J. Corvese
Independent Director
Independent Director
4.60K
--
Wright (Timothy R)
Wright (Timothy R)
Lead Independent Director
Lead Independent Director
2.77K
--
Dr. Garo H. Armen, Ph.D.
Dr. Garo H. Armen, Ph.D.
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
--
--
Mr. Richard Goldberg
Mr. Richard Goldberg
Chief Development Officer
Chief Development Officer
--
--
收入明細
單位: USD更新時間: 10月6日 週一
單位: USD更新時間: 10月6日 週一
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
業務USD
名稱
營收
佔比
Non-cash royalty revenue
24.83M
96.65%
Other services
526.00K
2.05%
Clinical product revenue
334.00K
1.30%
地區USD
名稱
營收
佔比
United States
25.16M
97.95%
Rest of World
526.00K
2.05%
業務
地區
業務USD
名稱
營收
佔比
Non-cash royalty revenue
24.83M
96.65%
Other services
526.00K
2.05%
Clinical product revenue
334.00K
1.30%
股東統計
更新時間: 58 分鐘前
更新時間: 58 分鐘前
持股股東
股東類型
持股股東
持股股東
佔比
The Vanguard Group, Inc.
8.06%
Invus Public Equities Advisors, LLC
3.34%
B. Riley Financial, Inc
2.38%
Morgan Stanley & Co. LLC
2.26%
Millennium Management LLC
1.58%
其他
82.38%
持股股東
持股股東
佔比
The Vanguard Group, Inc.
8.06%
Invus Public Equities Advisors, LLC
3.34%
B. Riley Financial, Inc
2.38%
Morgan Stanley & Co. LLC
2.26%
Millennium Management LLC
1.58%
其他
82.38%
股東類型
持股股東
佔比
Investment Advisor
17.87%
Investment Advisor/Hedge Fund
4.62%
Research Firm
4.39%
Hedge Fund
2.84%
Individual Investor
1.76%
Venture Capital
0.19%
Family Office
0.17%
Bank and Trust
0.09%
其他
68.07%
機構持股
更新時間: 10月1日 週三
更新時間: 10月1日 週三
報告期間
機構數
持股數
持股佔比
持股變動
2025Q3
325
9.55M
29.96%
-3.46M
2025Q2
332
9.29M
33.90%
-3.65M
2025Q1
345
9.68M
35.51%
-3.04M
2024Q4
351
8.87M
37.81%
-3.86M
2024Q3
360
8.97M
41.48%
-3.09M
2024Q2
356
9.47M
44.86%
-4.33M
2024Q1
365
10.95M
52.48%
-2.79M
2023Q4
382
11.94M
62.90%
-111.48K
2023Q3
392
12.65M
70.00%
-689.92K
2023Q2
391
12.38M
73.61%
-974.75K
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
The Vanguard Group, Inc.
2.53M
7.95%
-16.81K
-0.66%
Jun 30, 2025
Invus Public Equities Advisors, LLC
1.06M
3.34%
+564.25K
+112.85%
Jun 30, 2025
B. Riley Financial, Inc
756.96K
2.38%
+756.96K
--
Dec 31, 2024
Morgan Stanley & Co. LLC
719.75K
2.26%
+350.35K
+94.84%
Jun 30, 2025
Millennium Management LLC
504.51K
1.58%
+504.51K
--
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
489.68K
1.54%
-1.12M
-69.54%
Jun 30, 2025
Marshall Wace LLP
432.48K
1.36%
+432.48K
--
Jun 30, 2025
AQR Capital Management, LLC
430.88K
1.35%
-10.60K
-2.40%
Jun 30, 2025
BofA Global Research (US)
420.68K
1.32%
+220.33K
+109.97%
Jun 30, 2025
Armen (Garo H.)
338.69K
1.06%
+7.51K
+2.27%
Sep 19, 2025
查看更多
持股ETF
更新時間: 18 小時前
更新時間: 18 小時前
機構名稱
佔比
iShares Micro-Cap ETF
0.02%
iShares Russell 2000 Growth ETF
0%
iShares Russell 3000 ETF
0%
Invesco NASDAQ Future Gen 200 ETF
0%
Fidelity Enhanced Small Cap ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
0%
Schwab U.S. Small-Cap ETF
0%
SPDR Portfolio MSCI Global Stock Market ETF
0%
Global X Russell 2000 ETF
0%
Virtus LifeSci Biotech Clinical Trials ETF
0%
查看更多
iShares Micro-Cap ETF
佔比0.02%
iShares Russell 2000 Growth ETF
佔比0%
iShares Russell 3000 ETF
佔比0%
Invesco NASDAQ Future Gen 200 ETF
佔比0%
Fidelity Enhanced Small Cap ETF
佔比0%
iShares Core S&P Total U.S. Stock Market ETF
佔比0%
Schwab U.S. Small-Cap ETF
佔比0%
SPDR Portfolio MSCI Global Stock Market ETF
佔比0%
Global X Russell 2000 ETF
佔比0%
Virtus LifeSci Biotech Clinical Trials ETF
佔比0%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
Feb 15, 2024
Merger
20→1
Feb 15, 2024
Merger
20→1
Feb 15, 2024
Merger
20→1
Feb 15, 2024
Merger
20→1
公告日期
類型
比率
Feb 15, 2024
Merger
20→1
Feb 15, 2024
Merger
20→1
Feb 15, 2024
Merger
20→1
Feb 15, 2024
Merger
20→1
